A large selection of disease-modifying therapies are currently available in the MS market with a sizable range of attributes, potencies and safety profiles. Consequently, this set of DMTs typically can yield some relief from this chronic condition. 

Utilization of first-generation DMTs such as Avonex, Betaseron, Copaxone and Rebif is declining due to their comparatively poor safety, efficacy and administration profiles versus newer DMTs. Most are genericized, but still see some use in the first-line treatment setting, particularly for less severe cases of MS and especially where payer pressure is involved.